Clinical Trials Related to Cyclophosphamide

Related studies linked through entity extraction aliases.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Status: SUSPENDED
Phase: PHASE1

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Status: TERMINATED
Phase: PHASE1

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Status: TEMPORARILY_NOT_AVAILABLE
Phase: N/A

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Status: RECRUITING
Phase: PHASE1

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Status: TERMINATED
Phase: PHASE1

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Status: RECRUITING
Phase: PHASE3

......SMARTEST Trial......

Status: COMPLETED
Phase: PHASE2

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Status: NOT_YET_RECRUITING
Phase: PHASE2

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Genotype-guided Treatment in DLBCL

Status: RECRUITING
Phase: PHASE3

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Status: RECRUITING
Phase: PHASE1/PHASE2

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Status: RECRUITING
Phase: PHASE2

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Status: RECRUITING
Phase: PHASE3

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2